Gene · 3423
Papers1,392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 1,392
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oral and Poster Abstracts of the 13th ISNS European Regional Meeting. | Int J Neonatal Screen | 2025 | 40136636 | PubTator, text mining | PubMed |
| Space environment adaptability of 2D semiconductor materials. | Natl Sci Rev | 2025 | 40130186 | PubTator, text mining | PubMed |
| Immediate Dentin Sealing: Advancing Bonding Efficacy and Clinical Success. | Cureus | 2025 | 40026953 | PubTator, text mining | PubMed |
| Central Nervous System-Targeted Gene Therapy for the Treatment of Neurocognitive Deficits in Mucopolysaccharidosis Type II Mice. | Hum Gene Ther | 2025 | 40014367 | PubTator, text mining | PubMed |
| Cost-Effectiveness Analysis of Idursulfase for the Long-Term Treatment of Hunter Syndrome Using a Partitioned-Survival Model Approach in R. | Value Health Reg Issues | 2025 | 39978289 | PubTator, text mining | PubMed |
A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase. | Mol Genet Metab | 2025 | 39978165 | PubTator, text mining | PubMed |
| Oral trehalose improves histological and behavior symptoms of mucopolysaccharidosis type II in iduronate 2-sulfatase deficient mice. | Sci Rep | 2025 | 39929944 | PubTator, text mining | PubMed |
| Exploratory metabolomic profiling of plasma and urine in patients with mucopolysaccharidosis type II (Hunter syndrome): A pilot study. | Mol Genet Metab | 2025 | 39842066 | PubTator, text mining | PubMed |
| Epidemiology of Mucopolysaccharidosis Type II According to the Register of the Russian Federation. | Turk Arch Pediatr | 2025 | 39803987 | PubTator, text mining | PubMed |
| Human induced pluripotent stem cell line (PNUSCRi005-A) generated from severe type of Hunter syndrome patient carrying exonic deletion (exon 4-7 del) in in human iduronate 2-sulfatase gene. | Stem Cell Res | 2025 | 39793273 | PubTator, text mining | PubMed |
| Genetic and allelic heterogeneity in 248 Indians with skeletal dysplasia. | Eur J Hum Genet | 2025 | 39706863 | PubTator, text mining | PubMed |
| Understanding the P-Cluster of Vanadium Nitrogenase: an EPR and XAS Study of the Holo vs. Apo Forms of the Enzyme. | Chembiochem | 2025 | 39544119 | PubTator, text mining | PubMed |
| Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy. | J Inherit Metab Dis | 2025 | 39440439 | PubTator, text mining | PubMed |
| Editorial: Endo- and transcytotic pathways at the brain barriers. | Front Drug Deliv | 2024 | 40836977 | PubTator, text mining | PubMed |
| Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants. | Hum Genomics | 2024 | 39617925 | PubTator, text mining | PubMed |
| A Systematic Literature Review on the Global Status of Newborn Screening for Mucopolysaccharidosis II. | Int J Neonatal Screen | 2024 | 39449359 | PubTator, text mining | PubMed |
| The diagnosis and management of mucopolysaccharidosis type II. | Ital J Pediatr | 2024 | 39380047 | PubTator, text mining | PubMed |
| Production of active human iduronate-2-sulfatase (IDS) enzyme in Nicotiana benthamiana. | Sci Rep | 2024 | 39367006 | PubTator, text mining | PubMed |
| Genotype-phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey. | Mol Genet Metab | 2024 | 39303318 | PubTator, text mining | PubMed |
| Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review. | Int J Mol Sci | 2024 | 39201256 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3423/papers?page=4